Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate + biologic versus triple csDMARD therapy in methotrexate-insufficient response rheumatoid arthritis
2015-000863-15Phase 4Active
- Sponsor
- Strasbourg University Hospital
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methotrexate, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in rheumatoid arthritis (RA) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Low disease activity with steroid taper at 11 months. Started Aug 2015; status: active.
02
Drugs
methotrexate5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-000863-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000863-15.